falsefalse

Updates in Advanced Renal Cell Carcinoma from The 2022 International Kidney Cancer Symposium - Episode 2

Comparing IO/IO and IO/TKI Frontline Treatment in Advanced RCC

,

Moshe Ornstein, MD, MA, explains his reasoning for starting patients with advanced renal cell carcinoma on an IO/IO combination regimen.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Overview of the Frontline Management and Risk Stratification of Advanced Renal Cell Carcinoma (RCC)
    Now Viewing
    EP. 2: Comparing IO/IO and IO/TKI Frontline Treatment in Advanced RCC
    EP. 3: Updates from the CLEAR Study on Efficacy of Lenvatinib plus Pembrolizumab in Patients with Advanced RCC
    EP. 4: Lenvatinib Dosing Strategies in Frontline Advanced RCC Treatment
    EP. 5: Nivolumab plus Ipilimumab for Frontline Treatment of Advanced RCC: 5-Year Follow-Up from the CheckMate 214 Trial
    EP. 6: Managing Adverse Events of IO/IO Frontline Combination Therapies in Advanced RCC Treatment
    EP. 7: COSMIC-313: Frontline Triplet Therapy in Advanced RCC
    EP. 8: Emerging Data in Non-Clear Cell RCC Treatment
    EP. 9: Exciting Investigational Therapies in Advanced RCC

    Related Content:

    Updates in Advanced Renal Cell Carcinoma from The 2022 International Kidney Cancer SymposiumGenitourinary Cancers
    Dr Hall on Unmet Needs in Later-Line RCC
    Dr Beckermann on the Rationale for Evaluating Tivozanib/Nivolumab After IO-Based Therapy in RCC
    Sitravatinib/Nivolumab Shows Modest Activity in Progressive Metastatic Clear Cell RCC Before Trial Termination
    x